The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this
pathway represent the main treatment modality. Endocrine therapy has proven successful in …

Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive
intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor …

Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few
therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a …

Copper serves as a co-factor for a host of metalloenzymes that contribute to malignant
progression. The orally bioavailable copper chelating agent tetrathiomolybdate (TM) has …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

Squamous cell lung cancers (lung squamous cell carcinomas [LUSCs]) are associated with
high mortality and a lack of therapies specific to this disease. Although recurrent molecular …

As the field of translational 'omics has progressed, refined classifiers at both genomic and
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …

Abstract Bone metastases occur in 50–70% of patients with late-stage breast cancers and
effective therapies are needed. The expression of enhancer of zeste homolog 2 (EZH2) is …

Abstract Triple-Negative Breast Cancer (TNBC) has a poor prognosis and adverse clinical
outcomes among all breast cancer subtypes as there is no available targeted therapy …

Metabolic reprogramming is key for cancer development, yet the mechanism that sustains
triple-negative breast cancer (TNBC) cell growth despite deficient pyruvate kinase M2 …